Enhanced Ocular Delivery of Beva via Ultra‐Small Polymeric Micelles for Noninvasive Anti‐VEGF Therapy
Advanced Materials · 2024
DOI: 10.1002/adma.202314126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Ruhui Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Ophthalmology and Optometry, Eye Hospital, School of Biomedical Engineering, Wenzhou, Zhejiang Province, 325035, China. Hauptthemen laut MEDLINE: Micelles, Bevacizumab, Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Wenzhou Institute of UCAS, Zhejiang Provincial Natural Science Foundation of China, Wenzhou Science and Technology Plan Project.
Abstract (Originalsprache)
Pathological ocular neovascularization resulting from retinal ischemia constitutes a major cause of vision loss. Current anti‐VEGF therapies rely on burdensome intravitreal injections of Bevacizumab (Beva). Herein ultrasmall polymeric micelles encapsulating Beva (P@Beva) are developed for noninvasive topical delivery to posterior eye tissues. Beva is efficiently loaded into 11 nm micelles fabricated via self‐assembly of hyperbranched amphiphilic copolymers. The neutral, brush‐like micelles demonstrate excellent drug encapsulation and colloidal stability. In vitro, P@Beva enhances intracellular delivery of Beva in ocular cells versus free drug. Ex vivo corneal and conjunctival‐sclera‐choroidal tissues transport after eye drops are improved 23‐fold and 7.9‐fold, respectively. Anti‐angiogenic bioactivity is retained with P@Beva eliciting greater inhibition of endothelial tube formation and choroid sprouting over Beva alone. Remarkably, in an oxygen‐induced retinopathy (OIR) model, topical P@Beva matching efficacy of intravitreal Beva injection, is the clinical standard. Comprehensive biocompatibility verifies safety. Overall, this pioneering protein delivery platform holds promise to shift paradigms from invasive intravitreal injections toward simplified, noninvasive administration of biotherapeutics targeting posterior eye diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Ophthalmology and Optometry, Eye Hospital, School of Biomedical Engineering, Wenzhou, Zhejiang Province, 325035, China.
- Wenzhou Key Laboratory of Perioperative Medicine, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province, 325001, China.
- The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang Province, 324000, China.
- Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, 317000, China.
ORCID-Profile: Ruhui Yang, Sicheng Tang, Yuhua Tong, Xingjie Zan
Förderung
- Wenzhou Institute of UCAS
- Zhejiang Provincial Natural Science Foundation of China
- Wenzhou Science and Technology Plan Project
Zitieren
APA
Yang, R., Tang, S., Xie, X., Jin, C., Tong, Y., Huang, W., & Zan, X. (2024). Enhanced Ocular Delivery of Beva via Ultra‐Small Polymeric Micelles for Noninvasive Anti‐VEGF Therapy. Advanced Materials. https://doi.org/10.1002/adma.202314126
Vancouver
Yang R, Tang S, Xie X, Jin C, Tong Y, Huang W, et al. Enhanced Ocular Delivery of Beva via Ultra‐Small Polymeric Micelles for Noninvasive Anti‐VEGF Therapy. Advanced Materials. 2024. doi:10.1002/adma.202314126
BibTeX
@article{Yang2024,
author = {Yang, Ruhui and Tang, Sicheng and Xie, Xiaoling and Jin, Chaofan and Tong, Yuhua and Huang, Wenjuan and Zan, Xingjie},
title = {Enhanced Ocular Delivery of Beva via Ultra‐Small Polymeric Micelles for Noninvasive Anti‐VEGF Therapy},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202314126}
}
EUVIMED